Dr. Mark A. Terrelonge Jr., MD, MPH

Dr. Terrelonge practices at UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health.

Dr. Terrelonge's NPI, 1366837734, was assigned on April 2, 2015. Dr. Terrelonge graduated from Stanford University School Of Medicine in 2014. Dr. Terrelonge holds California license A146489.

Dr. Terrelonge's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights, at 505 Parnassus Ave, Box 0296, San Francisco, CA 94143 in San Francisco County. The practice phone is (415) 353-2733.

Dr. Terrelonge's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health. Dr. Terrelonge is also affiliated with Zuckerberg San Francisco General Hospital and Trauma Center. The medical group on file is UCSF Pediatrics. Dmand AI also links Dr. Terrelonge to 1 more hospital and 4 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Terrelonge practices, 3 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Terrelonge's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Terrelonge is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Terrelonge's licenses on file in 2 states: California and Hawaii.

Dmand AI lists fibromyalgia and chronic pain, hereditary polyneuropathy, lower back pain, mobility impairment, muscle disease, muscle pain, fibromyalgia, and limb pain, neck pain and spine problems and neuropathy among the conditions Dr. Terrelonge treats.

CMS data shows 450 Medicare services from Dr. Terrelonge across 10 procedure codes in 2024, for 137 Medicare patients. Medicare paid $26,524 for them.

CMS counts 137 Medicare patients who saw Dr. Terrelonge in 2024. The largest group is 65 to 74, with 55 patients. 74% of them have high cholesterol, and 67% have high blood pressure. 29% are also on Medicaid. Their average risk score is 1.70, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Terrelonge's median patient age at 66, with 51% women.

In 2024, Dr. Terrelonge wrote 395 Medicare Part D claims for 71 patients. 76% of them were for generic drugs. CMS names the drug for 276 of them, across 12 drugs with 11 or more claims each, at $920,854 in total drug cost. In 2023, CMS named 226 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. Terrelonge for performance year 2024, reported as part of a group. Dr. Terrelonge accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Terrelonge as offering telehealth.

Dmand AI links 6 papers to Dr. Terrelonge, published from 2022 to 2024. The most frequent topics are Delirium. Dr. Terrelonge's most frequent co-authors are Vanja Christopher Douglas, MD, Sara Lahue, MD and Laura Katherine Rosow, MD.

CMS Open Payments shows 1 general payment to Dr. Terrelonge from 1 drug or device company in 2020. Food and beverage make up the largest share, 100% of the total. Biogen, Inc. paid the most, $26.

Dr. Terrelonge graduated from Stanford University School Of Medicine in 2014.

Dr. Terrelonge is in network with 6 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.